fachmedien.de - spezialisierte Fachinformationen für Studium und Beruf
fachmedien.de - spezialisierte Fachinformationen für Studium und Beruf
fachmedien.de - spezialisierte Fachinformationen für Studium und Beruf
fachmedien.de - spezialisierte Fachinformationen für Studium und Beruf
fachmedien.de - spezialisierte Fachinformationen für Studium und Beruf

Site Breadcrumb

Verkauf durch Sack Fachmedien

Krentz / Hompesch

Translational Research Methods for the Metabolic Continuum

A Focus on Early Phase Clinical Drug Development

Medium: Buch
ISBN: 978-3-032-30499-5
Verlag: Springer
Erscheinungstermin: 30.10.2026
Jetzt vorbestellen
vorbestellbar, Erscheinungstermin ca. Oktober 2026
Auf die Merkliste Drucken

Leseprobe
Überschrift

Beschreibung

Kostenloser Versand

nach Deutschland, Österreich und in die Schweiz

Bequem zahlen

Rechnung, Kreditkarte, PayPal oder Bankeinzug

Wir sind gerne für Sie da

0800 000-1378 (Inland)
service@fachmedien.de
<<Kontaktformular>>

Fragen

Fragen Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua
Anwtorten

Anwtorten At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet

In this 3 edition, we position metabolic fatty liver disease (MAFLD) more prominently both as a component and driver of a metabolic continuum of non-communicable disorders. These include obesity, diabetes, cardiovascular, and renal disease.  All share common risk factors and are interconnected via complex – and often bidirectional – pathological processes.

The pivotal position of MAFLD reflects increasing awareness in recent years of (a) intersections between metabolic liver disease and the broader spectrum of cardiometabolic disorders and (b) the unmet need for effective new pharmacotherapies.  

Evidence from clinical trials of medications originally developed to treat obesity and diabetes points to the need for practical non-invasive methods for quantifying therapeutic effects on hepatic steatosis.  An intense drug development effort continues aimed at the clinically important subtype of non-alcoholic steatohepatitis (NASH) which carriesan increased risk of fibrosis, cirrhosis, and hepatocellular carcinoma. Moreover, MAFLD/NASH is recognized as a multisystem disease with myriad extrahepatic manifestations. The 3 edition will update all chapters with particular emphasis on expanding the chapters on hepato-cardio-renal and functional imaging; the chapter on isotopic tracer methodology will also be strengthened.  Relevant new chapters in a new section will address the future prospects for biomarkers to include proteomics, metabolomics, and genomics.  The potential of computational modeling in translational research will be covered alongside the value of real-world data in drug development and strategies for personalized precision management of diseases in the metabolic continuum. The book will continue our objective – established in the earlier editions – to remain at the forefront of clinical science that facilitates paradigm changes and provides leadership in translational research for cardiometabolic disorders.

Produkteigenschaften

  • Artikelnummer: 9783032304995
  • Medium: Buch
  • ISBN: 978-3-032-30499-5
  • Verlag: Springer
  • Erscheinungstermin: 30.10.2026
  • Sprache(n): Englisch
  • Auflage: Third Auflage 2026
  • Produktform: Gebunden
  • Seiten: 662
  • Format (B x H): 178 x 254 mm
  • Ausgabetyp: Kein, Unbekannt
  • Vorauflage: 978-3-030-11747-4

Themen

Autoren/Hrsg.

Herausgeber

1              Metabolic Continuum: A Conceptual Pathogenic Framework.- 2  Quantification of Insulin Action in Human Subjects.- 3         Assessment of Islet Alpha- and Beta-Cell Function in Humans.- 4 Pharmacokinetic and Pharmacodynamic Assessment of Novel and Biosimilar Insulins.- 5             Measurement of Energy Expenditure.- 6                Quantifying Appetite and Satiety.- 7         Non-invasive Quantitative Magnetic Resonance- and Ultrasound-based Biomarkers in Metabolic Dysfunction-associated Steatotic Liver Disease and Other Cardiometabolic Diseases Associated with Ectopic Fat Deposition.- 8             Structural and Functional Imaging of Muscle, Heart, Endocrine Pancreas and Kidneys in Drug Development for the Metabolic Continuum.- 9        Isotopic Tracers for the Measurement of Metabolic Flux Rates.- 10         Role of Tissue Biopsy in Drug Development for Metabolic Dysfunction-Associated Steatotic Liver Disease and Other Metabolic Disorders.- 11            Utility of Invasive and Non-invasive Cardiovascular Research Methodologies in Drug Development for The Metabolic Continuum.- 12              Omics: Potential Role in Early-Phase Drug Development for Obesity and Type 2 Diabetes.- 13    Early Phase Metabolic Research with Reference to Special Populations.- PART 2        Preclinical Drug Development and Transitioning to Clinical Studies.- 14    Sculpting the Metabolic Continuum – Translational Aspects.- 15             Animal Models of Type 2 Diabetes, Obesity And Metabolic Dysfunction-Associated Steatohepatitis – Clinical Translatability And Applicability In Preclinical Drug Development.- 16                Quantitative Approaches in Translational Cardiometabolic Research: An Overview.- 17     Regulatory Considerations for Early Study and Clinical Development of Drugs for Diabetes, Obesity, Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) and other Disorders in the Metabolic Continuum.- PART 3       Emerging Translational Research Methods and Real-World Therapeutic Considerations.- 18               Emerging Future Prospects for Translational Cardiometabolic Research: Real World Data to Inform Drug Development for the Metabolic Continuum.- 19 "Towards Precision Diagnosis and Management for the Metabolic Continuum: How Artificial Intelligence and Data Science are Revolutionizing Translational Medicine and Clinical Care.- 20     GLP-1 receptor agonists: role in the prevention and treatment of diabetes-related cardiovascular complications.